Recombinant factor VIIa for life-threatening hemorrhage in trauma patients: Review of the literature

European Journal of Trauma

Volumn 32, Issue 5, 2006, Pages 439-448

  Pape, Hans Christoph ^a   Erhardtsen, Elisabeth ^b   Meyer, Christian ^b   Leppäniemi, Ari Kalevi ^c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b NOVO NORDISK A S   (Denmark)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Blood transfusion; Coagulopathy; Hemorrhage; Recombinant factor VIIa; Trauma

Indexed keywords

PLACEBO; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADOLESCENT; ADULT; AGED; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD COMPONENT THERAPY; BLOOD TRANSFUSION; CEREBRAL SINUS THROMBOSIS; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMOSTASIS; HUMAN; INJURY; INTESTINE NECROSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; RANDOMIZED CONTROLLED TRIAL; REVIEW; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 33751562447     PISSN: 14390590     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00068-006-6009-1     Document Type: Review

References (56)

1. Sauaia A, Moore FA, Moore EE, et al. Epidemiology of trauma deaths: a reassessment. J Trauma 1995;38:185-93.
2. Peden M, McGee K, Sharma G. The injury chart book: a graphical overview of the global burden of injuries. Geneva: World Health Organization, 2002.
3. Champion HR. Epidemiological basis for future improvements in trauma care. Semin Hematol 2004;41(Suppl 1):173 [abstract].
4. Armand R, Hess JR. Treating coagulopathy in trauma patients. Transfus Med Rev 2003;17:223-31.
5. Hardy JF. Managing uncontrolled hemorrhage in trauma and surgery: a novel and promising approach. Can J Anaesth 2002;49: S4-6.
6. Grounds M. Recombinant factor VIIa (rFVIIa) and its use in severe bleeding in surgery and trauma: a review. Blood Rev 2003;17(Suppl 1):S13-21.
7. Lawson JH, Murphy MP. Challenges for providing effective hemostasis in surgery and trauma. Semin Hematol 2004;41(Suppl 1): 55-64.
8. Hoyt DB. A clinical review of bleeding dilemmas in trauma. Semin Hematol 2004;41(Suppl 1):40-3.
9. Moore FA, Moore EE, Sauaia A. Blood transfusion. An independent risk factor for postinjury multiple organ failure. Arch Surg 1997;132:620-5.
10. Como JJ, Dutton RP, Scalea TM, Edelman BB, Hess JR. Blood transfusion rates in the care of acute trauma. Transfusion 2004;44:809-13.
11. Claridge JA, Sawyer RG, Schulman AM, McLemore EC, Young JS. Blood transfusions correlate with infections in trauma patients in a dose-dependent manner. Am Surg 2002;68:566-72.
12. Shander A. Emerging risks and outcomes of blood transfusion in surgery. Semin Hematol 2004;41(Suppl 1):117-24.
13. Aiboshi J, Moore EE, Ciesla DJ, Silliman CC. Blood transfusion and the two-insult model of post-injury multiple organ failure. Shock 2001;15:302-6.
14. Smithies MN, Weaver CB. Role of the tissue factor pathway in the pathogenesis and management of multiple organ failure. Blood Coagul Fibrinolysis 2004;15:1-10.
15. Chiu J, Ketchum LH, Reid TJ. Transfusion-sparing hemostatic agents. Curr Opin Hematol 2002;9:544-50.
16. Erhardtsen E. Ongoing NovoSeven® trials. Intensive Care Med 2002;28(Suppl 2):S248-55.
17. Kristensen J, Killander A, Hippe E, Helleberg C, Ellegard J, Holm M, Kutti J, Mellqvist UH, Johansson JE, Glazer S, Hedner U. Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. Haemostasis 1996;26(Suppl 1):159-64.
18. Ingerslev J, Knudsen L, Hvid I, Tange MR, Fredberg U, Sneppen O. Use of recombinant factor VIIa in surgery in factor-VII-deficient patients. Haemophilia 1997;3:215-8.
19. Muleo G, Santoro R, Iannaccaro PG, Papaleo P, Leo F. The use of recombinant activated factor VII in congenital and acquired factor VII deficiencies. Blood Coagul Fibrinolysis 1998;9:389-90.
20. Peters M, Heijboer H. Treatment of a patient with Bernard-Soulier syndrome and recurrent nosebleeds with recombinant factor VIIa. Thromb Haemost 1998;80:352.
21. Jiménez-Yuste V, Villar A, Morado M, Canales M, Hernandez MC, Sanjurjo MJ, Quintana M, Hernandez-Navarro F. Continuous infusion of recombinant activated factor VII during caesarean section delivery in a patient with congenital factor VII deficiency. Haemophilia 2000;6:588-90.
22. Vidarsson B, Onundarson PT. Recombinant factor VIIa for bleeding in refractory thrombocytopenia. Thromb Haemost 2000;83:634-5.
23. Poon MC. Use of recombinant factor VIIa in hereditary bleeding disorders. Curr Opin Hematol 2001;8:312-8.
24. Poon MC. Management of thrombocytopenic bleeding: is there a role for recombinant coagulation factor VIIa? Curr Hematol Rep 2003;2:139-47.
25. Roberts HR, Monroe DM 3rd, Hoffman M. Safety profile of recombinant factor VIIa. Semin Hematol 2004;41:101-8.
26. Hoffman M, Monroe DM 3rd. A cell-based model of hemostasis. Thromb Hemost 2001;85:958-65.
27. Jurlander B, Thim L, Klausen NK, Persson E, Kjalke M, Rexen P, Jørgensen TB, Østergaard PB, Erhardtsen E, Bjørn SE. Recombinant activated factor VII (rFVIIa): characterization, manufacturing, and clinical development. Semin Thromb Hemost 2001;27: 373-84.
28. Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997;99:542-7.
29. Monroe DM, Hoffman M, Oliver JA, Roberts HR. A possible mechanism of action of activated factor VII independent of tissue factor. Blood Coagul Fibrinolysis 1998;9(Suppl 1):S15-20.
30. Clark AD, Gordon WC, Walker ID, Tait RC. 'Last-ditch' use of recombinant factor VIIa in patients with massive haemorrhage is ineffective. Vox Sang 2004;86:120-4.
31. Mayo A, Misgav M, Kluger Y, Geenberg R, Pauzner D, Klausner J, Ben-Tal O. Recombinant activated factor VII (NovoSeven™): addition to replacement therapy in acute, uncontrolled and life-threatening bleeding. Vox Sang 2004;87:34-40.
32. Dutton RP, McCunn M, Hyder M, D'Angelo M, O'Connor J, Hess JR, Scalea TM. Factor VIIa for correction of traumatic coagulopathy. J Trauma 2004;57:709-19.
33. Kulkarni R, Daneshmand A, Guertin S, Fath J, Atwal M, Melvin J, LaFrance S. Successful use of activated recombinant factor VII in traumatic liver injuries in children. J Trauma 2004;56:1348-52.
34. Eikelboom JW, Bird R, Blythe D, Coyle L, Gan E, Harvey M, Isbister J, Leahy M, McIlroy D, Rahimpanah F, Ramanthan S, Strasser S, Ward C, Watts A, Towler S, Yi Q. Recombinant activated factor VII for the treatment of life-threatening haemorrhage. Blood Coagul Fibrinolysis 2003;14:713-7.
35. Morenski JD, Tobias JD, Jimenez DF. Recombinant activated factor VII for cerebral injury-induced coagulopathy in paediatric patients. J Neurosurg 2003;98:611-6.
36. Martinowitz U, Kenet G, Lubetski A, Luboshitz J, Segal E. Possible role of recombinant activated factor VII (rFVIIa) in the control of hemorrhage associated with massive trauma. Can J Anaesth 2002;49:S15-20.
37. Kenet G, Walden R, Eldad A, Martinowitz U. Treatment of traumatic bleeding with recombinant factor VIIa. Lancet 1999;354:1879.
38. O'Neill PA, Bluth M, Gloster ES, Wali D, Priovolos S, DiMaio TM, Essex DW, Catanese CA, Strauss RA. Successful use of recombinant activated factor VII for trauma-associated hemorrhage in a patient without preexisting coagulopathy. J Trauma 2002;52:400-5.
39. Siegel LJ, Gerigk L, Tuettenberg J, Dempfle CE, Scharf J, Fiedler F. Cerebral sinus thrombosis in a trauma patient after recombinant activated factor VII infusion. Anesthesiology 2004;100:441-3.
40. Alcorn K, Aggarwal A. Single institution experience of recombinant activated factor VII (NovoSeven) in the management of intractable bleeding in surgical and trauma patients. Blood 2002;100:[Abstract No. 3840].
41. Dincer AP, Abu-Hajir M, Christians KK, Brasel KJ, Gotschall JL. Human recombinant activated factor seven, NovoSeven (rVIIa), in the management of massive bleeding despite adequate resuscitation in major trauma. Blood 2002;100:[Abstract No. 3918].
42. Aggarwal A, Catlett J, Alcorn K. Use of recombinant activated factor VII (rFVIIa) in the management of intractable bleeding in surgical and trauma patients. Blood 2001;98:[Abstract No. 3883].
43. Becton D, Saylors R, Morris J, Saccente S, Stine K. Treatment of bleeding with rFVIIa (NovoSeven®) in four diverse cases. Blood 2001;98:[Abstract No. 1104].
44. Kamphuisen PW, van den Akker JM, Kaasjager KAH, Bloemen TIF. Control of life-threatening pulmonary bleeding with activated recombinant factor VII. Am J Med 2002;112:332-3.
45. Martinowitz U, Kenet G, Segal E, Luboshitz J, Lubetsky A, Ingerslev J, Lynn M. Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma 2001;51:431-9.
46. Martinowitz U, Kenet G, Lubetzki A, Luboshitz J, Varon D. Recombinant activated factor VII (rFVIIa) for adjunctive hemorrhage control in trauma and surgery: the Israeli compassionate registry. Thromb Haemost 2001;86(Suppl): [Abstract No.2624].
47. Martinowitz U, Luboshitz J, Lubetsky A, Kenet G. New approach for the management of catastrophic bleeds in trauma and surgery: enhancement of coagulation at the site of injury by recombinant activated factor VII (rFVIIa). Blood 2001;98:827A-8A [Abstract No.3439].
48. Dutton RP, Hess JR, Scalea TM. Recombinant factor VIIa for control of haemorrhage: early experience in critically ill trauma patients. J Clin Anesth 2003;15:184-8.
49. Kenet G, Lubetsky A, Luboshitz J, Martinowitz U. A new approach to treatment of bleeding episodes in young haemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven). J Thromb Haemost 2003;1:450-5.
50. Sorensen B, Ingerslev J. Tailoring haemostatic treatment to patient requirements - an update on monitoring haemostatic response using thrombelastography. Haemophilia 2005; 11(Suppl 1):1-6.
51. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, Skolnick BE, Steiner T, for the Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators. Recombinant activated factor VII for acute intracerebral hemorrhage. N Eng J Med 2005;352:777-85.
52. Riou B, Boffard K, Warren B, Iau P, Kluger Y, Rossaint R, Axelsen M, Rizoli S, for the NovoSeven® Trauma Study Group. Recombinant factor VIIa (NovoSeven) as adjunctive therapy for bleeding control in trauma - a randomized, placebo-controlled trial. Shock 2004;21(Suppl 2):76-7 [Abstract No.227].
53. Boffard K, Warren B. Decreased transfusion utilization and improved outcome associated with the use of recombinant factor VIIa as an adjunct in trauma. J Trauma 2004;57:451 [Paper No. 59].
54. Roissant R, Boffard KD, Warren BL, Iau PT, Rizoli S, Sørensen TM, Kluger Y, Riou B. Decreased transfusion utilization using recombinant factor VIIa as an adjunct in trauma. Intensive Care Med 2004;30(Suppl 4):S199 [Abstract No. 771].
55. Boffard KD, Riou B, Warren B, Choong PI, Rizoli S, Rossiant R, Axelsen M, Kluger Y, on behalf of the NovoSeven® Trauma Study Group. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-control led, double-blind clinical trials. J Trauma 2005;59:8-18.
56. Meng ZH, Wolberg AS, Monroe DM III, Hoffman M. The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. J Trauma 2003;55:886-91.